J&J wins EU backing for PARP combo Akeega in prostate cancer—but only in some patients

Johnson & Johnson is starting the PARP inhibitor race in prostate cancer from a weak position.

Drug reviewers at the European Medicines Agency (EMA) have recommended an approval for the combination of Zejula and Zytiga for treating metastatic castration-resistant prostate cancer (mCRPC). But in a notable restriction, only patients with BRCA1/2-mutated tumors will be eligible for the drug combo after the European Commission’s expected authorization.